Nautilus Biotechnology Raises $76 Million in Series B Funding to Be the First to Quantify the Human Proteome
Gene Editing Revamped with CRISPR Prime Editor – Result Is A High Efficiency, More Precise Gene Editor With Versatile Editing Capabilities And Lower Off-Target Effects
2019 in Review – Major Acquisitions, Population Studies, Gigantic Founding Rounds, Technological Advancements, and ….
BC Platforms Aims to Advance Clinical Decision-Making by Enhancing Clinical Data with Genomics Information
An interview with Michael Snyder, Stanford W. Ascherman Professor and Chair, Department of Genetics & Director, Center for Genomics and Personalized Medicine